

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



WUXI BIOLOGICS (CAYMAN) INC.

藥明生物技術有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2269)

**ANNOUNCEMENT
UPDATE ON THE QUALIFICATIONS OF
COMPANY SECRETARY**

Reference is made to the announcements of the Company dated November 20, 2018 and June 5, 2019 in relation to, among other things, the waiver granted to the Company by The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) from strict compliance with the requirements under Rules 3.28 and 8.17 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) in respect of the acting of Mr. Huang Yue (“**Mr. Huang**”) as the company secretary of the Company (“**Previous Qualification Waiver**”). The Previous Qualification Waiver was for a period of three years from November 20, 2018 to November 19, 2021.

The board of directors (the “**Board**”) of the Company is pleased to announce that the Stock Exchange has confirmed that Mr. Huang is qualified to act as the company secretary of the Company under Rule 3.28 of the Listing Rules.

By order of the Board
WuXi Biologics (Cayman) Inc.
Dr. Ge Li
Chairman

Hong Kong, November 16, 2021

As at the date of this announcement, the Board comprises Dr. Zhisheng Chen and Dr. Weichang Zhou as executive Directors; Dr. Ge Li, Dr. Ning Zhao, Mr. Yibing Wu and Mr. Yanling Cao as non-executive Directors; and Mr. William Robert Keller, Mr. Teh-Ming Walter Kwauk and Mr. Kenneth Walton Hitchner III as independent non-executive Directors.

* *For identification purpose only*